Receive alerts
Market Cap:
£69.9 m
52 weeks high
52 weeks low

Viewing results 1-25 of 54


Maxcyte fighting cancer battle on two fronts via experimental targeted treatment and technology licensing deals

In May 2019, Maxcyte saw the second cohort of patients begin dosing in a phase I trial using its lead MCY-M11 cancer immunotherapy...

2 weeks ago

MaxCyte making "significant progress" commercially and in the clinic

In the opening six months MaxCyte generated revenues of US$8.4mln via licensing deals, up 21%...

on 17/7/19
Retail & consumer

Immuno-oncology: All you wanted to know but were too afraid to ask

Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers...

on 27/5/19

MaxCyte starts dosing second cohort of patients in early-stage trial of its lead cancer drug

There were no safety concerns from the first set of patients enrolled into the trial, so MaxCyte is to up the dose for those in the second cohort as planned...

on 8/5/19

MaxCyte shows off CARMA platform at industry conference in Washington DC

One of CARMA’s key differentiators is that it can be used to manufacture drug candidates within a single day, providing a “meaningful reduction” in wait times for patients...

on 1/5/19

MaxCyte looks ahead to “pivotal” 2019 with demand for its cell engineering platform on the rise

MaxCyte licenses out its Flow Electroporation technology to help other companies develop drugs, but it also develops its own treatments, the first of which recently entered the clinic...

on 24/4/19

MaxCyte launches latest iteration of its Flow Electroporation cell editing technology

Flow Electroporation is used in gene editing and allows almost any molecule – such as DNA, RNA or proteins – to be delivered into any cell with minimal cell disturbance...

on 8/4/19

MaxCyte extends relationship with Gilead Sciences-owned cancer drug developer Kite

Kite will use MaxCyte's Flow Electroporation cell engineering platform to help it develop “multiple” CAR-T drug candidates for up to ten targets...

on 1/3/19

MaxCyte raises £10mln in share placing to accelerate growth strategy

The cell-based medicines developer raised the funds through the placing of around 5.8mln new shares at a price of 170p each...

on 6/2/19

MaxCyte says earnings likely to beat expectations after bumper end to the year

Revenues increased 19% year-on-year to US$16.7mln in the 12 months to December 31, with top-line growth of 25% in the second six months...

on 15/1/19

MaxCyte updates on plans to simplify share structure

MaxCyte currently has two classes of shares: unrestricted and Regulation S restricted...

on 21/11/18

MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments

The company has partnered with Precision Biosciences of the US...

on 14/11/18

MaxCyte inks research agreement with Gilead subsidiary Kite Pharma

The AIM-listed bioscience firm said under the agreement Kite would use its Flow Electroporation Technology platform to enable non-viral cell engineering...

on 12/11/18

CRISPR Therapeutics to use MaxCyte’s technology in its search for cancer gene therapies

CRISPR will use MaxCyte’s Flow Electroporation technology to deliver its components into T-cells, which are known to attack the body’s own cells that have been infected by viruses...

on 9/11/18

MaxCyte doses first phase I patient

The dose-escalation study is taking place in the US ...

on 10/10/18

MaxCyte on track to start first-ever clinical trial before the end of the year

The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma...

on 24/9/18

CAR-T therapies: All you wanted to know and were too afraid to ask

Immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations...

on 6/9/18

MaxCyte gears up for first clinical trial after gaining regulatory green light

The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours...

on 16/7/18

MaxCyte hails US National Institutes of Health tie-up to find treatment for sickle cell disease

The collaboration will be with National Heart, Lung and Blood Institute, which is part of the NIH...

on 11/6/18

MaxCyte pre-clinical data shows correction of sickle cell disease mutation

Pre-clinical data presented Friday (May 18) at an industry assessed the use of non-viral CRISPR-mediated gene-correction in the treatment of the blood disorder...

on 21/5/18

MaxCyte appoints Infinity Pharma's Claudio Dansky Ullmann as its chief medical officer

Ullmann was most recently the senior vice president and head of clinical development at Infinity Pharmaceuticals Inc, where he oversaw all clinical development and operations...

on 25/4/18